{"id":1586,"date":"2022-05-01T10:45:04","date_gmt":"2022-05-01T01:45:04","guid":{"rendered":"http:\/\/tarumi.co.jp\/blog\/?p=1586"},"modified":"2024-08-27T08:10:14","modified_gmt":"2024-08-27T08:10:14","slug":"post-1586","status":"publish","type":"post","link":"https:\/\/tarumi.co.jp\/blog\/?p=1586","title":{"rendered":"\u8d64\u8272\u5149\u306b\u3088\u308b\u8fd1\u8996\u6cbb\u7642"},"content":{"rendered":"\r\n

\u77ed\u6ce2\u9577\u306e\u30d0\u30a4\u30aa\u30ec\u30c3\u30c8\u30e9\u30a4\u30c8\u304c\u8fd1\u8996\u3092\u6291\u5236\u3059\u308b\u306e\u306f\u6709\u540d\u3060\u304c\u3001\u8d64\u8272\u5149\u3082\u52b9\u679c\u304c\u3042\u308b\u3068\u3044\u3046\u767a\u8868(Ophthalmology\u8a8c)<\/a>\u3067\u3042\u3063\u305f\u306e\u3067\u3001\u7d39\u4ecb\u3057\u307e\u3059\u3002<\/p>\r\n\r\n\r\n\r\n

Participants: <\/strong>Two hundred sixty-four eligible children 8 to 13 years of age with myopia of cycloplegic spherical equivalent refraction (SER) of -1.00 to -5.00 diopters (D), astigmatism of 2.50 D or less, anisometropia of 1.50 D or less, and best-corrected visual acuity (BCVA) of 0.0 logarithm of the minimum angle of resolution or more were enrolled in July and August 2019. Follow-up was completed in September 2020.
Methods: <\/strong>Children were assigned randomly to the intervention group (RLRL treatment plus single-vision spectacle [SVS]) and the control group (SVS). The RLRL treatment was provided by a desktop light therapy device that emits red light of 650-nm wavelength at an illuminance level of approximately 1600 lux and a power of 0.29 mW for a 4-mm pupil (class I classification) and was administered at home under supervision of parents for 3 minutes per session, twice daily with a minimum interval of 4 hours, 5 days per week.

\uff18\u6b73\u301c\uff11\uff13\u6b73\u306e\u8fd1\u8996264\u4f8b\u3067
\u300c\u773c\u93e1\u88c5\u7528\uff0b\u9031\uff15\u56de1\u65e5\uff12\u56de\uff13\u5206\u305a\u3064\u8d64\u8272\u5149\u3092\u898b\u308b\u300d
\u3000\u3000 vs
\u300c\u773c\u93e1\u88c5\u7528\u306e\u307f\u300d
\u3092\u6bd4\u8f03\u3057\u305f\u3002<\/p><\/blockquote>\r\n\r\n\r\n\r\n

\u305d\u306e\u7d50\u679c\u3001<\/p>\r\n\r\n\r\n\r\n

Results: <\/strong>Among 264 randomized participants, 246 children (93.2%) were included in the analysis (117 in the RLRL group and 129 in the SVS group). Adjusted 12-month axial elongation and SER progression were 0.13 mm (95% confidence interval [CI], 0.09-0.17mm) and -0.20 D (95% CI, -0.29 to -0.11D) for RLRL treatment and 0.38 mm (95% CI, 0.34-0.42 mm) and -0.79 D (95% CI, -0.88 to -0.69 D) for SVS treatment. The differences in axial elongation and SER progression were 0.26 mm (95% CI, 0.20-0.31 mm) and -0.59D (95% CI, -0.72 to -0.46 D) between the RLRL and SVS groups. No severe adverse events (sudden vision loss \u22652 lines or scotoma), functional visual loss indicated by BCVA, or structural damage seen on OCT scans were observed.<\/p>

Conclusions: <\/strong>Repeated low-level red-light therapy is a promising alternative treatment for myopia control in children with good user acceptability and no documented functional or structural damage.<\/p>

1\u5e74\u5f8c

\u300c\u773c\u93e1\u88c5\u7528\uff0b\u9031\uff15\u56de1\u65e5\uff12\u56de\uff13\u5206\u305a\u3064\u8d64\u8272\u5149\u3092\u898b\u308b\u300d\u306f\u773c\u8ef8\u95770.13mm\u4f38\u9577
\u3000\u3000 vs
\u300c\u773c\u93e1\u88c5\u7528\u306e\u307f\u300d\u306f\u3001\u773c\u8ef8\u95770.38mm\u4f38\u9577

\u300c\u773c\u93e1\u88c5\u7528\uff0b\u9031\uff15\u56de1\u65e5\uff12\u56de\uff13\u5206\u305a\u3064\u8d64\u8272\u5149\u3092\u898b\u308b\u300d\u306f\uff0d0.20D\u9032\u884c
\u3000\u3000 vs
\u300c\u773c\u93e1\u88c5\u7528\u306e\u307f\u300d\u306f\u3001\uff0d0.79D\u9032\u884c<\/p><\/blockquote>\r\n\r\n\r\n\r\n

\u3053\u308c\u306f\u3001\u576a\u7530\u5148\u751f\u306e\u30d0\u30a4\u30aa\u30ec\u30c3\u30c8\u30e9\u30a4\u30c8<\/a>\u8ad6\u6587(cf.Table S2)\u3088\u308a\u3082\u52b9\u679c\u304c\u3042\u308b(\u3088\u3046\u306b\u307f\u3048\u308b)\u3002650nm\u306e\u8d64\u8272\u5149\u30e9\u30f3\u30d7\u306f\u7c21\u5358\u306b\u88fd\u9020\u3067\u304d\u3001\u8fd1\u8996\u6cbb\u7642\u306e\u6717\u5831(\u304b\u3082\u3057\u308c\u306a\u3044)\u3002<\/p>\r\n\r\n\r\n\r\n

\u2191\u3067\u3001\u5965\u6b6f\u306b\u3082\u306e\u3092\u631f\u3093\u3067\u3044\u308b\u7406\u7531\u306f<\/p>\r\n\r\n\r\n\r\n